Sylvie Bove, new CEO of EIT Health Blog Post

Sylvie Bove has been appointed as new CEO of the EIT Health, the Knowledge and Innovation Community (KIC) for healthy living and active aging, promoted by the European Institute of Innovation and Technology (EIT). The Spanish node, EIT Health Spain, headed by the University of Barcelona (UB) with the support from Biocat, has its headquarters at Barcelona Science Park (PCB) and is composed of 50 core partners and 90 associate partners from the public and private sectors, leaders in their fields and committed to innovation in health. Bove took on the position on September 1

 

Montserrat Vendrell leaves PCB to join the new Barcelona Institute of Science and Technology as General Director Blog Post

Montserrat Vendrell leaves the direction of the Barcelona Science Park (PCB) to head the Barcelona Institute of Science and Technology (BIST), a new scientific institution result of the confluence of six Catalan research centres. The Chairman of the BIST is Dr. Rolf Tarrach, former dean of Physics and vice rector of the University of Barcelona (UB), and currently President of the European University Association (EUA). Dr. Vendrell will take up her new post mid-September. 

 

The 14th edition of the Spend the Summer at the Park! starts Blog Post

The welcome ceremony to participants of the Spend the summer at the Park! program was held today, Wednesday, July 1. The aim of this initiative –organized annually by the Barcelona Science Park (PCB)– is to bring research closer to students of any university in the world through their participation in projects currently being carried out in research groups, research centers and companies based at the PCB.

PCB presents Research In Society Program as part of offer of activities of School Activities Program for the 2015- 2016 school year Blog Post

Yesterday, the Parc Cientific de Barcelona presented at Cosmocaixa the proposals in the field of dissemination of science for the next school year of its Research in Society program as part of the School Activities Programme 2015-206 (acronym in Spanish PAE) of the Pedagogical Co-ordination Council, promoted by the Barcelona City Council, through the Barcelona Municipal Institute of Education. The workshop, aimed at teachers, was aimed at bringing together professionals teaching at institutions that are part of the CCP -a network composed of 147 entities Barcelona- in order to provide them with first-hand information of educational proposals that are at their disposal in the city.

The Ordesa Foundation collaborates with Doctors Without Borders to improve the nutrition of Congolese children Blog Post

The Ordesa Foundation will finance 34,000 units of prepared therapeutic food (RUTF) that Doctors Without Borders (MSF) will distribute to children suffering from severe acute malnutrition in the Democratic Republic of Congo. The partnership is part of the work conducted by the Ordesa Foundation to provide funding and advocacy, through direct aid, to projects aimed at children without resources. Since 2007, the Ordesa Group has R&D&i center at Barcelona Science Park (PCB), from which it is actively involved in clinical studies and national and international programs to improve people´s health and quality of life, especially in maternal and infant stage.

 

Anna Taratiel explores the relationship between art and science through her art work at the Barcelona Science Park Blog Post

Anna Taratiel, one of the leading representatives of the global movement of the street art, has finished the work at the  Barcelona Science Park (PCB) that was started last October. It is a large dimensions mural covering the walls of the central aisle –measuring over 80 meters in length and that connects the Cluster I and Cluster II PCB buildings, where many laboratories of the different centers, companies and research institutes installed in the park converge.

 

 

Ordesa saw turnover grow to €112.4 millions, up 4.7%, in 2014 Blog Post

Laboratorios Ordesa today announced its results for the 2014 year, which reveal a growing trend mainly due to increased sales, cutting structural costs, implementing more efficient sales policies and consolidating foreign markets the company had opened in previous years. Since 2007, the Ordesa Group has a R&D&i center at Barcelona Science Park, from where the company actively participates in clinical studies and national and international research projects in the areas of immunology and cognitive development. The elaboration of hydrolyzed cereals, liquid milk, or the launching of the first porridge with bifidus effect, and supplemented infant formulas are some of the results from these projects. 

Genetic “editing” a new tool to fight inherited disease Blog Post

Researchers at the Hospital Clínic, IDIBAPS, the Hospital Sant Joan de Deu and the Institute for Bioengineering of Catalonia (IBEC) have participated in a study, led by Dr. Juan Carlos Izpisúa Belmonte of the Gene Expression Laboratory at California’s Salk Institute, that uses molecular scissors to remove mitochondrial mutations in mouse eggs. In the study, published today in the journal Cell (doi: 10.1016/j.cell.2015.03.051), researchers developed a simple technique to eliminate mitochondrial mutations in eggs or embryos at an early stage of development.

Ordesa leads the Smartfoods project Blog Post

The Centre for the Development of Industrial Technology (CDTI) has granted the Smartfoods industrial research project for the development of smart food to a consortium of companies led by Ordesa from this R&D&i center at Parc Científic de Barcelona.The aim of this research is the design of foods and screening tests that will help reduce the risk of some of the most frequently occurring diseases that will cause 3 of every 4 deaths in 2020.

Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome Blog Post

Avizorex Pharma, a biopharmaceutical company developing novel therapeutics for Dry Eye Disease, has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye Syndrome (DES) with a new mechanism of action currently undergoing late-stage preclinical studies. Avizorex Pharma is an ophthalmology biotech backed by Inveready Venture Capital with headquarters in Elche (Alicante, Spain) and offices at Barcelona Science Park (PCB).